Pharmaceuticals, Biotechnology and Life Sciences
59 percent complete response rate in a subset of patients withendoscopically unresectable low-grade upper tract urothelial cancer(UTUC).
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,announced that on May 3, 2019 the Compensation Committee of Puma’s Boardof Directors approved the grant of inducement restricted stock unitawards covering an aggregate of 49,125 shares of Puma common stock tonine new non-executive employees.
Dicerna Pharmaceuticals Board of Directors approved the grant of inducement stockoptions to purchase a total of 145,500 shares of common stock to bedistributed among eight new employees
Approval based on data showing Kadcyla cut the risk of diseaserecurring by half compared to Herceptin in the adjuvant setting forspecific patients with HER2-positive early breast cancer
Health Canada hasapproved the supplemental New Drug Submission that expands the use ofADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin,vinblastine and dacarbazine) chemotherapy in patients with previouslyuntreated Stage IV Hodgkin lymphoma (HL).
Sanofi’s dengue vaccien Dengvaxia was approved in the USA, the company said in a press release Thursday.
– Preclinical results support development of AB-2004 as potential treatment for gastrointestinal dysfunction and associated behavioral symptoms of Autism Spectrum…
FSD Pharma delays 2018 Year-End Filings, working with new auditing firm in advance of listing on the NYSE
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CBD?src=hash” target=”_blank”gt;#CBDlt;/agt;–Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announced the appointment…
Cellgene and bluebird bio are are encouraged by the expansion and persistence ofthe CAR T-cells, as well as the deep and durable responses with amanageable safety profile we’ve seen for bb2121 to date